ConvaTec (GB:CTEC) has released an update.
ConvaTec Group PLC has announced an upgrade to its full-year 2024 guidance, forecasting stronger organic sales growth between 7.25% and 8.0% and improved operating margins. The company attributes this positive outlook to a diverse product portfolio, new product launches, and enhanced operational efficiency, which are expected to result in double-digit earnings per share growth in 2024 and 2025. ConvaTec’s divisions, including Advanced Wound Care and Continence Care, continue to show promising growth, supported by new product introductions and strategic market initiatives.
For further insights into GB:CTEC stock, check out TipRanks’ Stock Analysis page.
